结果

“结果”可以独立作为一个部分,或者和讨论部分合二为一。“结果”和讨论部分还可以分成小节,使用较短精悍的标题。

  • 如同“方法”部分一样,可以使用小标题来区分不同实验的结果。
  • 在阐述结果时,应注意其逻辑顺序。一般地,可根据结果的重要性进行排序,而不一定必须按实验的前后实施顺序排列。在描述结果时应使用过去时;不过,在提及图表时使用现在时。
  • 不要无谓重复图、表和正文中已提及的资料。一个常犯的错误是:把表中已列举的数据在正文中又重复提及。正确的做法是:在正文中对表内资料进行总结,或,仅提及一、两项最重要的资料点。通常表要比正文更一目了然。
  • 正文中应纳入统计分析的结果,对具有统计学意义的比较结果提供P值。

Example

Source

Hitesh N Appaiah, Chirayu P Goswami, Lida A Mina, Sunil Badve, George W Sledge, Yunlong Liu and Harikrishna Nakshatri. Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Research, 2011 Sep 13;13(5):R86. Publisher full text

Results

miRNA and small RNA expression analyses

Earlier studies showing the presence of miR-21 and miR-155 in the serum/plasma of patients with cancer [25,26] prompted us to evaluate their levels in the sera of healthy subjects and patients with breast cancer. U6, 5S, miR-16, RNU66, RNU49, RNU19, and SNORD44 levels were also analyzed in these samples to identify a small RNA expressed at a similar level in equal volume of sera from both healthy subjects and patients with cancer to serve as a normalization control. Among these, miR-16 has previously been used as a normalization control for serum miRNA profiling studies [25]. RNU66, RNU48, and RNU19 were undetectable. miR-16 is one of the most abundant miRNAs in the serum (average cycle threshold (CT) of 24) compared with any other RNA analyzed, and the abundance of this miRNA in the serum was similar between healthy subjects and patients with cancer (Table 4 and Figure 1a)...

Serum U6 and 5S in relation to ER/PR and nodal status of primary tumors

We next determined whether the upregulation of U6 and 5S observed above is unique to specific subtypes of breast cancer. ER/PR status of 36 tumors, out of 39 patient samples used in the study, was known; 24 and 12 were ER/PR+ and ER/PR-, respectively. In this subgroup analysis, U6, but not 5S, levels were higher in the sera of patients with ER/PR+ breast cancer compared with healthy subjects with or without normalization with miR-16 and SNORD44 (Table 5 and Figure 3). Despite a small sample size, sera of patients with ER/PR- demonstrated elevated U6 and 5S levels compared with healthy subjects when miR-16 or SNORD44 was used as an internal control (Table 5 and Figure 3). miR-21 level was similar between healthy subjects and patients with cancer of either subtype. Note that the differences in the levels of these RNAs between ER/PR+ and ER/PR- were not statistically significant (data not shown)...

U6 levels are elevated in sera of patients with breast cancer, irrespective of metastasis

We collected sera from 15 healthy subjects, 15 clinically disease-free patients with breast cancer, and 15 patients with stage IV metastatic disease. RNA from the three groups (cohort 2) was prepared at the same time from an equal volume of sera. The cDNA was prepared with 25 ng of RNA and analyzed for the levels of U6, 5S, miR-21, and miR-16. In this cohort, as with the first cohort, U6 level was significantly elevated in the sera of clinically disease-free patients with breast cancer without normalization (Table 6 and Figure 4) (5.35-fold, P = 3.09 x 10-5) or with normalization with SNORD44 (6.6-fold, P = 0.00028)...

There is a famous saying in English: "A picture is worth a thousand words." This means that, sometimes, an image can explain your findings far better than text could. So make good use of figures and tables in your manuscript! However, avoid including redundant figures and tables (e.g., two showing the same thing in a different format), or using figures and tables where it would be better to just include the information in the text (e.g., where there is not enough data for a table or figure).

Submit a manuscript Sign up for article alerts